Gleevec

Generic name: Imatinib
Dosage form: tablet
Drug class: BCR-ABL tyrosine kinase inhibitors

Usage of Gleevec

Gleevec is a targeted therapy cancer treatment used to treat specific types of leukemia (blood cancer), bone marrow disorders, skin cancers and certain tumors of the stomach and digestive system.

Gleevec (imatinib) is an oral tablet that is taken once or twice a day.

Gleevec works by interfering with specific proteins that help tumors grow and spread through the body; they come from the family of medicines called BCR-ABL tyrosine kinase inhibitors. Gleevec was a groundbreaking cancer treatment when it was first FDA approved on May 10, 2001.

Gleevec is used to treat specific types of these cancers:

Chronic Myeloid (myelogenous) Leukemia (Ph+ CML)

Acute Lymphoblastic Leukemia (ALL)

Myelodysplastic / Myeloproliferative Diseases (MDS/MPD)

Aggressive Systemic Mastocytosis (ASM)

Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL)

Dermatofibrosarcoma Protuberans (DFSP)

Gastrointestinal Stromal Tumors (GIST)

Gleevec (imatinib) is now available as a generic.

Gleevec side effects

Get emergency medical help if you have signs of an allergic reaction to Gleevec (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).

Call your doctor at once if you have:

fluid retention--shortness of breath (even while lying down), swelling, rapid weight gain;

kidney problems--little or no urination, swelling in your feet or ankles;

fluid build-up in the lungs--pain when you breathe, wheezing, gasping for breath, cough with foamy mucus;

liver problems--upper stomach pain, loss of appetite, dark urine, jaundice (yellowing of the skin or eyes);

low blood cell counts--fever, cold or flu symptoms, easy bruising, unusual bleeding, mouth sores, pale skin, unusual tiredness, feeling light-headed, cold hands and feet;

signs of stomach bleeding--bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;

signs of tumor cell breakdown--confusion, weakness, muscle cramps, nausea, vomiting, fast or slow heart rate, decreased urination, tingling in your hands and feet or around your mouth; or

thyroid symptoms--tiredness, dry skin, hair loss, constipation, depression, slow heart rate, weight gain, feeling more sensitive to cold temperatures.

Imatinib can affect growth in children and teenagers. Tell your doctor if your child is not growing at a normal rate while using this medicine.

Common Gleevec side effects may include:

fluid retention;

nausea, vomiting, stomach pain, diarrhea;

joint or muscle pain;

skin rash; or

feeling tired.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Gleevec

You should not use Gleevec if you are allergic to imatinib.

Tell your doctor if you have ever had:

liver disease (especially hepatitis B);

kidney disease;

underactive thyroid, recent or upcoming thyroid surgery;

heart disease, high blood pressure, congestive heart failure;

a stomach ulcer or bleeding;

diabetes; or

chemotherapy.

You may need to have a negative pregnancy test before starting this treatment.

Do not use Gleevec if you are pregnant. It could harm the unborn baby or cause birth defects. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 14 days after your last dose.

Do not breast-feed a baby while you are using Gleevec and for at least 1 month after your last dose.

Relate drugs

How to use Gleevec

Usual Adult Gleevec Dose for Chronic Myelogenous Leukemia:

Chronic phase: 400 mg orally once a day Accelerated phase or blast crisis: 600 mg orally once a day A dose increase may be considered in the absence of a severe adverse drug reaction and severe non-leukemia related Neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time), failure to achieve a satisfactory hematologic response after at least 3 months of treatment, failure to achieve a cytogenetic response after 6 to 12 months of treatment, or loss of a previously achieved hematologic or cytogenetic response: -Disease progression chronic phase: 600 mg orally once a day -Disease progression accelerated phase or blast crisis: 400 mg orally 2 times a day Uses: -Newly diagnosed patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase -Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy

Usual Adult Dose of Gleevec for Acute Lymphoblastic Leukemia:

600 mg orally daily Use: For relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Usual Adult Dose of Gleevec for Myeloproliferative Disorder:

400 mg orally once a day Comments: -Determine PDGFRb gene rearrangements status prior to initiating therapy. Use: For patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements

Usual Adult Dose of Gleevec for Myelodysplastic Disease:

Usual Adult Dose of Gleevec for Systemic Mastocytosis:

-For patients with ASM without the D816V c-Kit mutation: 400 mg orally daily -If c-Kit mutational status is not known or unavailable: 400 mg orally daily may be considered for patients with ASM not responding satisfactorily to other therapies. -For patients with ASM associated with eosinophilia, a clonal hematological disease related to the fusion kinase FIP1L1-PDGFR alpha, a starting dose of 100 mg/day is recommended. Dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy. -For patients with ASM associated with eosinophilia (a clonal hematological disease related to the fusion kinase FIP1L1-PDGFR alpha: 100 mg orally daily; a dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy Comments: -Determine D816V c-Kit mutation status prior to initiating treatment. Use: For patients with aggressive systemic mastocytosis without the D816V c-Kit mutation

Usual Adult Dose of Gleevec for Hypereosinophilic Syndrome:

-For patients with HES/CEL: 400 mg orally daily -For patients with HES/CEL with demonstrated FIP1L1-PDGFR alpha fusion kinase: 100 mg orally daily; dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy Use: For patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR alpha fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR alpha fusion kinase negative or unknown

Usual Adult Dose of Gleevec for Chronic Eosinophilic Leukemia:

Usual Adult Dose of Gleevec for Dermatofibrosarcoma Protuberans:

100 mg orally daily Use: For patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)

Usual Pediatric Dose of Gleevec for Chronic Myelogenous Leukemia:

1 year and older: 340 mg/m2 orally once a day or 170 mg/m2 orally 2 times a day Maximum Dose: 600 mg daily Comments: -Therapy can be given as a once daily dose or the daily dose may be split into 2 doses, with one portion dosed in the morning and one portion in the evening. -There is no experience with this drug in children under 1 year of age. Use: -Newly diagnosed patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase.

Warnings

Gleevec can lower blood cells that help your body fight infections and help your blood to clot. You may get an infection or bleed more easily. Call your doctor if you have unusual bruising or bleeding, or signs of infection (fever, chills, body aches).

Gleevec may increase the risk of liver problems. Tell your doctor if you have upper stomach pain, loss of appetite, dark urine, clay-colored stools, or jaundice (yellowing of the skin or eyes).

Gleevec may increase the risk of fluid retention or heart problems. Tell your doctor if you have swelling or rapid weight gain, shortness of breath, fast or slow heart rate, weak pulse, or fainting.

What other drugs will affect Gleevec

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Tell your doctor about all your current medicines. Many drugs can have interactions with Gleevec, especially:

an antibiotic, antifungal, or antiviral medicine;

seizure medicine;

a blood thinner such as warfarin (Coumadin, Jantoven); or

a vitamin or mineral supplement that contains iron.

This list is not complete and many other drugs may interact with imatinib. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.